Combined entity bolsters expertise to help Pharma optimize commercial performance in the face of mounting regulatory and commercial pressures on net revenue
Address the intricacies of the Gross-to-Net process design and enable industry-leading practices for revenue management within your organization
Get insights into new and revised regulations and guidance released, impacting drug manufacturers participation in government programs.
Its Branded Drugs Prescription Fee (BPDF) season. Discover key dates, considerations and guidance on how your organization can handle this.
Navigate CMS guidance on Medicare Part D Manufacturer Discount Program. Learn steps for participation or check eligibility for Phase-In Discounts.
Stay informed on our latest conference discussion on the BP Stacking Proposal, its potential implications and considerations for pharma manufacturers.
A deep dive into the intricacies of aggregating discounts, compliance challenges, operational considerations, and financial implications.
Stay informed on critical developments in pharmaceutical pricing, explore recent cases, and delve into hot topics, key trends, and best practices.
Discover the impacts of the Inflation Reduction Act 2022 on pharmaceutical industry focusing on key provisions affecting Prescription Drugs and GTN.
Discover latest trends and updates in BFSF and FMV. Understand their impact on government pricing calculations, reimbursement, and compliance.
OIG reports on ASP data accuracy and CMS oversight—what manufacturers need to know. Get insights and recommendations for pricing accuracy.